HOPE-Epilepsy Trial (HOPE-Epilepsy)
High Dose Omega 3 Fatty Acids Supplementation in Patients With Epilepsy : The HOPE-Epilepsy Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
São Paulo, Brazil, 04005-909
- Research Institute, Hospital do Coração
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with active Epilepsy
Exclusion Criteria:
- pregnant women or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Placebo
|
|
Experimental: Omega 3 fatty acids supplementation
Omega 3 fatty acids capsules
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Seizure Frequency
Time Frame: 18 months
|
number of seizures during the treatment period
|
18 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of Life
Time Frame: 12 months
|
12 months
|
|
|
categorized seizure frequency
Time Frame: 18 months
|
number of crises categorized as: generalized, focal with disconnection and focal without disconnection
|
18 months
|
|
Percentage of overall seizure frequency modification
Time Frame: 18 months
|
percentage of reduction or increase in seizure frequency from baseline til the end of treatment period
|
18 months
|
|
Time Free of seizures during treatment
Time Frame: 12 months
|
12 months
|
|
|
Reduction in seizure frequency
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: M J Carrion, MD, Hospital do Coracao
- Study Chair: O Berwanger, PhD, Hospital do Coracao
- Study Chair: R D Lopes, PhD, BCRI
- Study Chair: F A Scorza, PhD, Federal University of São Paulo
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HCor
- Research Institute - HCor (Other Identifier: HCor)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.